February 12, 2026 (Global) – Baxter International Inc. has issued a cautious profit outlook for fiscal 2026, forecasting adjusted earnings that fall short of Wall Street expectations as persistent product challenges and softer demand weigh on its performance. The medical products company’s stock slid sharply after the announcement, reflecting investor concern over ongoing operational headwinds.
“We need to get better. And we are not satisfied with our current performance,” said Baxter CEO Andrew Hider during the company’s earnings call, underscoring the urgency of addressing the firm’s near‑term challenges.
Baxter projected adjusted earnings per share in the range of $1.85 to $2.05 for 2026, notably below analysts’ consensus of approximately $2.25, according to industry data. The firm also forecast flat to 1% sales growth for the year, down from the roughly 5.6% growth recorded in 2025 and trailing expectations for revenue of about $11.31billion.
One of the key headwinds cited by Baxter is uncertainty surrounding its Novum infusion pump, which remains under shipment holds due to safety concerns and a serious U.S. recall issued last year after reports of injuries and fatalities. This unresolved issue is expected to continue throughout 2026, impacting product availability and customer confidence.
In addition to the infusion pump situation, demand for Baxter’s IV solutions segment has weakened, in part due to lasting changes in clinical practices and lingering effects from a 2024 disruption at a major manufacturing facility following Hurricane Helene. The company’s IV solutions volumes have not returned to previous levels, prompting management to reassess its expectations for this core product category.
For the fourth quarter of 2025, Baxter reported adjusted earnings of $0.44 per share, below market forecasts, although revenue of $2.97billion exceeded estimates, offering a mixed view of current performance. The company anticipates that the first quarter of 2026 will be particularly challenging, with improvements expected in the latter parts of the year as cost‑cutting measures and operational adjustments take effect.
Market analysts noted that the combination of the earnings performance miss and the softer full‑year guidance contributed to a sell‑off in Baxter’s shares, placing pressure on investor sentiment. The company also announced changes to its board of directors in conjunction with the earnings release, part of broader efforts to strengthen leadership as Baxter navigates its strategic challenges.
Industry observers highlight that Baxter’s outlook underscores broader pressures faced by medical device companies navigating regulatory scrutiny, product recalls and shifting demand dynamics, particularly in hospital‑based supply segments. Going forward, analysts will be closely watching how Baxter’s operational initiatives and product pipelines respond to these headwinds to restore growth and confidence among stakeholders.
